Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

110.67 +3.05 (+2.83%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 19,545,215
Open 108.26
Bid (Size) 110.68 (1)
Ask (Size) 110.88 (1)
Prev. Close 107.62
Today's Range 106.84 - 112.00
52wk Range 66.01 - 119.96
Shares Outstanding 1,253,809,440
Dividend Yield 2.86%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
From Pomerantz LLP
Via GlobeNewswire
Gilead Stock Rises On US Supreme Court Ruling In Favor Of Health Insurers Covering Preventive Care
Jefferies termed the Supreme Court’s ruling an ‘incremental positive’ for Gilead that removes an overhang going into the launch for Yeztugo. 
Via Stocktwits

Performance

YTD
+20.5%
+20.5%
1 Month
+2.1%
+2.1%
3 Month
-1.0%
-1.0%
6 Month
+17.6%
+17.6%
1 Year
+60.8%
+60.8%

More News

Read More
Why This Looming Supreme Court Decision Could Rattle Gilead Sciences
Via Investor's Business Daily
Trump Vows To Cut 'The Best Deal' On Drug Prices. What To Expect.
Via Investor's Business Daily
Topics Government
44 Public Companies Make Time's Most Influential List: Coinbase, UFC, Nintendo, Netflix And More Stocks Investors Can Buy
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
Via ACCESS Newswire
Gilead Sciences, Inc. proudly Supports Unite for HER's Metastatic Breast Cancer Sustainer Program
Via 24-7 Press Release
4 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Gilead Sciences Signs $750M Deal For Cancer Drug With Kymera Therapeutics, Predicts Hit To Its Annual Profit
Via Stocktwits
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
Via ACCESS Newswire
Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies
Via Benzinga
Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
From Gilead Sciences, Inc.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
Via ACCESS Newswire
If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
From Pomerantz LLP
Via GlobeNewswire
5 Insightful Analyst Questions From Gilead Sciences’s Q1 Earnings Call
Via StockStory
Topics Earnings Intellectual Property World Trade
The FDA Shake-Up Continues, And Could Impact Genetic Medicines
Via Investor's Business Daily
Topics Government
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
Via ACCESS Newswire
FDA Approves Gilead's 'Game Changing' Twice-Yearly Shot To Prevent HIV Transmission, Critics Slam $28K Price Tag
Via Benzinga
GILEAD SCIENCES INC (NASDAQ:GILD) – A Quality Stock Worth Considering
Via Chartmill
Gilead Earns Analyst Praise As FDA Clears Yeztugo For Biannual HIV Prevention
Via Stocktwits
Gilead Sciences Wins Approval For Highly Effective HIV Prevention Drug
Via Investor's Business Daily
Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection
From Gilead Sciences, Inc.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
From Pomerantz LLP
Via GlobeNewswire
Gilead's HIV Prevention Drug Could Be Manufactured At Shocking Low Cost: Report
Via Benzinga

Frequently Asked Questions

Is Gilead Sciences publicly traded?
Yes, Gilead Sciences is publicly traded.
What exchange does Gilead Sciences trade on?
Gilead Sciences trades on the Nasdaq Stock Market
What is the ticker symbol for Gilead Sciences?
The ticker symbol for Gilead Sciences is GILD on the Nasdaq Stock Market
What is the current price of Gilead Sciences?
The current price of Gilead Sciences is 110.67
When was Gilead Sciences last traded?
The last trade of Gilead Sciences was at 06/27/25 04:00 PM ET
What is the market capitalization of Gilead Sciences?
The market capitalization of Gilead Sciences is 138.76B
How many shares of Gilead Sciences are outstanding?
Gilead Sciences has 139B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.